KUALA LUMPUR: Y.S.P. Southeast Asia Holding
Bhd (YSPAH) remains optimistic that the growth prospects of pharmaceutical products will continue.
The pharmaceutical company added that it will take cautious approaches in reviewing and monitoring market conditions to be in line with changing market trends.
YSPAH’s net profit rose 11.7% to RM12.4mil, or earnings per share of 8.76 sen against RM11.1mil, or 7.86 sen a year ago.
Revenue for the quarter expanded 3.3% to RM79.6mil from RM77.1mil.
The group's revenue increased by 10.4% to RM175.2 million from RM158.6 million when compared to the same period last year mainly due to higher sales from domestic and overseas market
For the first half of 2023, the group recorded a net profit of RM23.2mil compared with RM17.6mil in the same period last year due to higher sales from domestic and overseas markets and foreign exchange gain resulting from the weakening of the ringgit against the US dollar.
Its revenue increased by 10.4% to RM175.2mil from RM158.6mil when compared to the same period last year mainly due to higher sales from domestic and overseas markets.
